[CongressionalUNOFFICIAL BillsCOPY 119th22 Congress]RS [FromBR 2422 A RESOLUTION declaring the U.S.week of May 1 to 7, 2022, to be Tardive Dyskinesia Awareness Week.

GovernmentWHEREAS, Publishingmany Office]people [H.with serious, chronic mental illness, such as schizophrenia, bipolar disorder, severe depression, and gastrointestinal disorders, including gastroparesis, nausea, and vomiting, require treatment with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics;

Res.and WHEREAS, although ongoing treatment with these medications can be helpful and even lifesaving, for many people it can also lead to Tardive Dyskinesia;

1265and IntroducedWHEREAS, inTardive HouseDyskinesia (IH)]is <DOC>a 119thmovement CONGRESSdisorder 2dthat Sessionis H.characterized by random, involuntary, and uncontrolled movements of different muscles in the face, trunk, and extremities;

RES.and WHEREAS, Tardive Dyskinesia can develop months, years, or decades after a person starts taking DRBAs and even after discontinuing use of those medications.

1265Not Expressingeveryone supportwho fortakes thea designationDRBA ofdevelops theTardive weekDyskinesia, ofbut Mayif 3,it 2026,develops, throughit Mayis 9,often 2026,permanent; as ``Tardive Dyskinesia Awareness Week''.

_______________________________________________________________________and INWHEREAS, THEit HOUSEis OFestimated REPRESENTATIVESthat Mayover 7,600,000 2026Americans Mr.suffer from Tardive Dyskinesia.

PetersAccording (forto himself,the Mr.National Alliance for Mental Illness, one in every four patients receiving long-term treatment with an antipsychotic medication will experience Tardive Dyskinesia;

Bilirakis,and Mr.WHEREAS, years of difficult and challenging research have resulted in recent scientific breakthroughs, with two new treatments for Tardive Dyskinesia approved by the United States Food and Drug Administration;

Mullin,and WHEREAS, Tardive Dyskinesia is often unrecognized and Mr.patients suffering from the illness are commonly misdiagnosed.

BeanRegular ofscreening Florida)for submittedTardive Dyskinesia in patients taking DRBA medications is recommended by the followingAmerican resolution;Psychiatric Association;

whichand wasWHEREAS, referredby todeclaring Tardive Dyskinesia Awareness Week, the CommitteeHouse onof EnergyPage and1 Commerceof _______________________________________________________________________2 RESOLUTIONXXXX ExpressingJacketed supportUNOFFICIAL forCOPY the22 designationRS ofBR the2422 weekRepresentatives ofcan Mayraise 3,awareness 2026,of throughTardive MayDyskinesia 9,in 2026,the aspublic ``Tardiveand Dyskinesiain Awarenessthe Week''.medical community;

WhereasNOW, manyTHEREFORE, peopleBe livingit withresolved seriousby mentalthe illnessesHouse (forof example,Representatives bipolarof disorder,the majorGeneral depressiveAssembly disorder,of schizophrenia,the andCommonwealth schizoaffectiveof disorder)Kentucky: or gastrointestinal disorders (for example, gastroparesis, upset stomach, nausea, and vomiting) may be treated with medications that work as dopamine receptor blocking agents, including antipsychotics and antiemetics;

Whereas,Section while1. ongoing treatment with these medications can be necessary, prolonged use may be associated with tardive dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, and fingers or toes;

WhereasThe evenHouse mildof symptomsRepresentatives does hereby designate the week of TDMay can1 impactto people7, physically,2022, socially,to andbe emotionally;Tardive Dyskinesia Awareness Week.

WhereasSection it2. is estimated that TD affects approximately 600,000 people in the United States, and approximately 60 percent of people with TD have not been diagnosed, making it important to raise awareness about the symptoms;

WhereasThe itHouse isof importantRepresentatives thatencourages peopleeach takingindividual thesein medicationsthe beUnited monitoredStates forto TDbe bybetter ainformed health care provider, and regularaware screeningof forTardive TDDyskinesia. is recommended by the American Psychiatric Association;

WhereasPage clinical2 research has led to approval of treatments2 forXXXX adultsJacketed with TD by the Food and Drug Administration, and recognition and treatment of TD can make a positive impact in the lives of many people experiencing psychotic and mood disorders;

and Whereas the House of Representatives can raise awareness of TD among the public and medical community:

Now, therefore, be it Resolved, That the House of Representatives-- (1) expresses support for the designation of ``Tardive Dyskinesia Awareness Week'';

and (2) encourages each individual in the United States to become better informed about and aware of tardive dyskinesia.

<all>